ResearcherWenzhou Medical UniversityActive in the last 2 years

Jiawei Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6268-5912; OpenAlex author ID A5066597184. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Comprehensive analysis identifies AMIGO2 as a potential prognosis biomarker of pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-2025-7 ↗
Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. Co-author DOI 10.1186/s12935-022-02839-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guang Jer Wu · 2 shared papers, 2022–2025 · strength 0.40
- Paper Comprehensive analysis identifies AMIGO2 as a potential prognosis biomarker of pancreatic adenocarcinoma. DOI 10.21037/jgo-2025-7 ↗
- Paper Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. DOI 10.1186/s12935-022-02839-w ↗
Lan Li · 2 shared papers, 2022–2025 · strength 0.40
- Paper Comprehensive analysis identifies AMIGO2 as a potential prognosis biomarker of pancreatic adenocarcinoma. DOI 10.21037/jgo-2025-7 ↗
- Paper Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. DOI 10.1186/s12935-022-02839-w ↗
Haihua Gu · 1 shared paper, 2022 · strength 0.15
- Paper Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. DOI 10.1186/s12935-022-02839-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.